Bio-venture RudaCure joins hands with veterinary drug leaders Onhil and Onhil Pet for animal drug development

RudaCure Inc. (CEO Yongho Kim), a bio-venture company specializing in sensory disorder diseases, has signed a comprehensive MOU for veterinary drug development, production, and sales with Onhil Co., Ltd. (CEOs Kim Do-hyung and Yoo Jeong-woo) and Onhil Pet Co., Ltd. (CEOs Ko Hyun-gyu and Ryu Tae-seong), companies specializing in veterinary pharmaceutical clinical trials and distribution.

Under this agreement, the three companies will initially co-develop treatments for companion animals, including ear inflammation treatments, dry eye and corneal damage treatments, and dermatological formulations.

RudaCure Inc., which holds drug development know-how and patents, will be responsible for drug development, while Onhil Co., Ltd. and Onhil Pet Co., Ltd. will handle veterinary clinical trials, production, and sales.

RudaCure Inc. already has licensing experience with dry eye disease treatments and corneal damage treatments in 2021 and 2023, and is currently also developing a best-in-class powerful non-narcotic analgesic. The company is also actively conducting research on psoriasis and atopic dermatitis, and has recently been selected for the 2023 K-Bio Health Regional Center Support Program announced by Incheon Technopark, receiving support for prototype development, patents and certifications, and clinical trials. Additionally, the company has been selected for KOTRA's foreign investment attraction support program and plans to actively pursue overseas investment attraction activities.

Onhil Co., Ltd. is a companion animal healthcare platform company based on veterinary medicine under the vision of "One health. One happiness." The company is already supplying "DuraHeart SR-3," the world's first 3-month long-acting heartworm vaccine developed with a domestic patent, to animal hospitals. Going forward, the company plans to continue bringing good veterinary medicine-based products to market and grow into a company that contributes more to companion animal health.

Through the MOU among three companies with strong technology and sales capabilities, it is expected that specialized veterinary drug development in the expanding companion animal pharmaceutical market will contribute to a healthy and happy coexistence between companion animals and humans.